Direct Switch from Abilify 5mg to Rexulti 1mg
Yes, you can switch directly from aripiprazole (Abilify) 5mg to brexpiprazole (Rexulti) 1mg, but gradual cross-titration is strongly preferred over an abrupt switch to minimize risk of symptom destabilization and optimize tolerability.
Switching Strategy
The most recent international guidelines emphasize that antipsychotic switching should involve gradual cross-titration informed by the half-life and receptor profile of each medication 1. This is particularly relevant when switching between two D2 partial agonists like aripiprazole and brexpiprazole.
Why Gradual Cross-Titration Matters
Both aripiprazole and brexpiprazole are D2 partial agonists, but brexpiprazole displays less intrinsic activity at D2 receptors compared to aripiprazole 2, 3. This pharmacodynamic difference means:
- An abrupt switch could theoretically cause transient dopaminergic instability
- Gradual overlap allows the patient's system to adjust to the different receptor binding profiles
- Cross-titration minimizes risk of symptom breakthrough or withdrawal phenomena
Recommended Cross-Titration Approach
Week 1-2:
- Continue aripiprazole 5mg daily
- Start brexpiprazole 1mg daily (add on)
- Monitor for tolerability, particularly akathisia or sedation
Week 3:
- Reduce aripiprazole to 2.5mg daily OR discontinue entirely
- Continue brexpiprazole 1mg daily
- Given aripiprazole's long half-life (75 hours), it will take approximately 2 weeks to clear even after discontinuation
Week 4 onward:
- Discontinue aripiprazole if not already stopped
- Continue brexpiprazole 1mg as monotherapy
- Assess therapeutic response at 4 weeks minimum 1
Clinical Evidence Supporting This Switch
A Japanese study specifically examined switching from aripiprazole to brexpiprazole and found the transition to be safe with minimal metabolic abnormalities, low risk of extrapyramidal symptoms, and minimal changes in psychiatric symptoms 4. The study used a 4-week switching period, supporting the gradual approach outlined above.
Additionally, case series data suggest that patients with insufficient outcomes on aripiprazole may benefit from switching to brexpiprazole, with improvements in tolerability and reduction in depressive symptoms 5.
Key Monitoring Points
During the switch (Weeks 1-4):
- Akathisia/restlessness: Both drugs can cause this, but the overlap period may transiently increase risk
- Sedation: Brexpiprazole may cause more somnolence than aripiprazole 6
- Orthostatic hypotension: Monitor blood pressure, especially in elderly patients 6
- Psychiatric symptom stability: Watch for any breakthrough psychotic symptoms or mood destabilization
After the switch (Week 4+):
- Weight and metabolic parameters: Brexpiprazole shows modest weight gain (NNH=17 for ≥7% weight gain) 2
- Prolactin levels: Generally minimal effects with both agents 4
- Extrapyramidal symptoms: Lower risk with brexpiprazole compared to full D2 antagonists 3
Common Pitfalls to Avoid
Abrupt discontinuation of aripiprazole: While technically possible given both are partial agonists, this increases risk of symptom destabilization unnecessarily
Inadequate trial duration: The guidelines emphasize that therapeutic response should be assessed after at least 4 weeks at therapeutic dose 1. Don't judge efficacy prematurely.
Ignoring drug interactions: If the patient is on strong CYP3A4 or CYP2D6 inhibitors, brexpiprazole dose adjustments may be needed 6. However, note that for MDD indications, dose adjustment for CYP2D6 inhibitors is already factored into general dosing recommendations.
Overlooking the reason for switch: If switching due to inadequate efficacy on aripiprazole, consider whether switching to another D2 partial agonist is the right strategy. Guidelines suggest switching to compounds with different pharmacodynamic profiles (e.g., amisulpride, risperidone, paliperidone, or olanzapine) when a D2 partial agonist fails 1.
Alternative Consideration
If the patient failed aripiprazole due to lack of efficacy rather than tolerability, switching to another D2 partial agonist (brexpiprazole) may not be optimal. The 2025 INTEGRATE guidelines specifically recommend that for patients whose first-line treatment was a D2 partial agonist, a second-line treatment with amisulpride, risperidone, paliperidone, or olanzapine might be considered 1. Brexpiprazole would be more appropriate if the switch is driven by tolerability issues (akathisia, activation) rather than pure efficacy concerns.